Compare Sterling Biotech with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs SUVEN LIFESCIENCES - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH SUVEN LIFESCIENCES STERLING BIOTECH/
SUVEN LIFESCIENCES
 
P/E (TTM) x -0.4 19.4 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 STERLING BIOTECH   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
SUVEN LIFESCIENCES
Mar-19
STERLING BIOTECH/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs11338 3.1%   
Low Rs3169 2.0%   
Sales per share (Unadj.) Rs26.852.1 51.4%  
Earnings per share (Unadj.) Rs-15.06.8 -219.0%  
Cash flow per share (Unadj.) Rs-5.58.6 -63.7%  
Dividends per share (Unadj.) Rs01.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs54.965.3 84.1%  
Shares outstanding (eoy) m267.87127.28 210.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.9 5.3%   
Avg P/E ratio x-0.537.1 -1.3%  
P/CF ratio (eoy) x-1.329.6 -4.3%  
Price / Book Value ratio x0.13.9 3.3%  
Dividend payout %022.0 0.0%   
Avg Mkt Cap Rs m1,86232,272 5.8%   
No. of employees `0001.41.1 125.1%   
Total wages/salary Rs m547661 82.7%   
Avg. sales/employee Rs Th5,303.36,132.2 86.5%   
Avg. wages/employee Rs Th403.8611.1 66.1%   
Avg. net profit/employee Rs Th-2,959.0803.5 -368.3%   
INCOME DATA
Net Sales Rs m7,1816,635 108.2%  
Other income Rs m43242 17.6%   
Total revenues Rs m7,2236,877 105.0%   
Gross profit Rs m9471,604 59.0%  
Depreciation Rs m2,543221 1,148.7%   
Interest Rs m4,37738 11,610.3%   
Profit before tax Rs m-5,9311,587 -373.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,924718 -268.0%   
Profit after tax Rs m-4,007869 -460.8%  
Gross profit margin %13.224.2 54.5%  
Effective tax rate %32.445.2 71.7%   
Net profit margin %-55.813.1 -425.8%  
BALANCE SHEET DATA
Current assets Rs m14,3356,232 230.0%   
Current liabilities Rs m49,8091,490 3,342.7%   
Net working cap to sales %-494.071.5 -691.2%  
Current ratio x0.34.2 6.9%  
Inventory Days Days40386 466.7%  
Debtors Days Days17183 206.6%  
Net fixed assets Rs m55,4324,043 1,371.0%   
Share capital Rs m268127 210.4%   
"Free" reserves Rs m13,9358,183 170.3%   
Net worth Rs m14,7018,310 176.9%   
Long term debt Rs m9,47818 53,246.3%   
Total assets Rs m73,98810,389 712.2%  
Interest coverage x-0.443.1 -0.8%   
Debt to equity ratio x0.60 30,097.6%  
Sales to assets ratio x0.10.6 15.2%   
Return on assets %0.58.7 5.7%  
Return on equity %-27.310.5 -260.5%  
Return on capital %-6.419.5 -32.9%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,8605,622 33.1%   
Fx outflow Rs m251,799 1.4%   
Net fx Rs m1,8353,822 48.0%   
CASH FLOW
From Operations Rs m1,719356 483.5%  
From Investments Rs m-3,148-279 1,130.0%  
From Financial Activity Rs m1,426-225 -633.5%  
Net Cashflow Rs m-3-148 2.3%  

Share Holding

Indian Promoters % 33.9 63.4 53.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 9.9 0.0 -  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 36.5 107.7%  
Shareholders   21,482 37,287 57.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS